Maze Therapeutics Raises $115M in Series D Financing

Maze Therapeutics, a South San Francisco, CA-based clinical-stage biopharmaceutical company leveraging human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and metabolic diseases, closed a $115m Series D financing that included the conversion of issued convertible notes previously purchased by existing investors.

The round was co-led by investors Frazier Life Sciences and Deep Track Capital. Janus Henderson Investors and Logos Capital also participated. Existing investors include Third Rock Ventures, ARCH Venture Partners, Matrix Capital Management, GV, General Catalyst, Andreessen Horowitz (a16z), Foresite Capital, Woodline Partners LP, Casdin Capital, Piper Heartland Healthcare Capital, Moore Strategic Ventures, as well as other existing leading healthcare investors.

This latest funding will support the advancement of Maze’s lead programs, MZE829 and MZE782. MZE829, an oral, APOL1 inhibitor, is being evaluated as a treatment for APOL1 kidney disease (AKD), including in patients with focal segmental glomerulosclerosis (FSGS), with a Phase 2 trial expected to begin by the first quarter of 2025. MZE782 is an oral SCL6A19 inhibitor that Maze is evaluating in a Phase 1 healthy volunteer trial with plans to evaluate it as a treatment for chronic kidney disease (CKD) as well as phenylketonuria (PKU). Data from the Phase 1 trial is expected in the second half of 2025.

Led by Jason Coloma, Ph.D., chief executive officer, Maze Therapeutics is a clinical-stage biopharmaceutical company leveraging human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. The company is advancing a pipeline using its Compass platform, which provides insights into the genetic variants in disease and links them with the biological pathways that drive disease in specific patient groups. The company’s pipeline is led by two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for patients.

FinSMEs

03/12/2024